Hepatocellular carcinoma
Not recruitingStudy on Hepatocellular Carcinoma: Evaluating Livmoniplimab and Budigalimab for Patients with Advanced or Metastatic Cancer After First-Line Treatment
Study on Hepatocellular Carcinoma: Evaluating Livmoniplimab and Budigalimab for Patients with Advanced or Metastatic Cancer After First-Line Treatment
- Disease:Hepatocellular carcinoma
- Substances:BudigalimabLenvatinib+2
Italy- Participants:18–64 years · 65+ years
- Substances:Budigalimab
- Sponsor:AbbVie Deutschland GmbH & Co. KG














